Heart Transplantation for Early-Onset Anthracycline-Induced Cardiomyopathy Within 5 Months of Chemotherapy Completion

Anu K Kaskinen; Emmi Helle; Jaana Pihkala; Timo Jahnukainen; Jukka Kanerva; Mikko I Mäyränpää; Karl Lemström; Ilkka Mattila; Tiina Ojala

doi:10.1016/j.jaccas.2021.07.004

Heart Transplantation for Early-Onset Anthracycline-Induced Cardiomyopathy Within 5 Months of Chemotherapy Completion

JACC Case Rep. 2021 Nov 3;3(15):1677-1679. doi: 10.1016/j.jaccas.2021.07.004.

Authors

Anu K Kaskinen¹, Emmi Helle^{1

2}, Jaana Pihkala¹, Timo Jahnukainen¹, Jukka Kanerva¹, Mikko I Mäyränpää³, Karl Lemström^{4

5}, Ilkka Mattila¹, Tiina Ojala^{1

5}

Affiliations

¹ New Children's Hospital and Pediatric Research Center, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
² Stem Cells and Metabolism Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland.
³ Pathology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
⁴ Heart and Lung Center, Cardiac Surgery, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
⁵ Transplantation Laboratory, Haartman Institute, University of Helsinki, Helsinki, Finland.

Abstract

A 9-year-old boy developed progressive anthracycline-induced cardiomyopathy three months after completion of chemotherapy for osteosarcoma. Five months after completion of chemotherapy, at the age of 10 years, heart transplantation was performed. At 29 months since transplantation, the patient remains free of rejection and recurrence of osteosarcoma. (Level of Difficulty: Intermediate.).

Keywords: ACM, anthracycline-induced cardiomyopathy; EF, ejection fraction; EMB, endomyocardial biopsy; FS, fractional shortening; HF, heart failure; HTx, heart transplantation; LV, left ventricle/ventricular; acute heart failure; cancer; cardiac transplantation; cardiomyopathy; pediatric surgery.